Unknown PHASE4 INTERVENTIONAL 2-arm NCT00758927

The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients

The Effects of OMACOR on the LDL Sub-fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia

Sponsor: Inje University

Conditions Diabetes Mellitus, Type 2 Hypercholesterolemia Hypertriglyceridemia

Interventions Omega-3 acid 4 grams per day Placebo control

Updated 6 times since 2017 Last updated: Aug 3, 2009 Started: Jul 31, 2009 Primary completion: Apr 30, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00758927, this PHASE4 trial focuses on Diabetes Mellitus, Type 2 and Hypercholesterolemia and remains ongoing. Sponsored by Inje University, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Inje University
Kuhnil Pharmaceutical Co., Ltd.

Data source: Inje University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Busan, South Korea